Explore our flagship contract research and manufacturing capabilities—transforming complex botanical matrices into commercially validated, regulatory-compliant healthcare formulations.
Global biopharma, nutraceutical, and dermato-cosmetic brands are actively pivoting from crude herbal powders toward clinically backed, standardized, and structurally stable molecular complexes.
Traditional herbal preparations are often constrained by low intestinal permeability, rapid first-pass hepatic metabolism, and degradation in gastric acid. Advanced CDMOs now apply pharmaceutical delivery mechanisms to natural actives:
Modern consumers and tier-1 regulators reject ambiguous botanical ratios. OEM formulation development demands multi-wavelength chromatographic mapping to eliminate adulteration and establish chemical consistency:
Moving away from trial-and-error bench mixing, pharmaceutical QbD defines the Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) across the entire manufacturing lifecycle:
International procurement directors across North America, the European Union, Japan, and Australasia encounter distinct statutory minefields when commercializing botanical formulations.
Navigating Dietary Supplement Health and Education Act (DSHEA) and 21 CFR Part 111 cGMP compliance demands ironclad analytical substantiation:
The European pharmacopeia establishes the most stringent chemical contaminant and impurity limits worldwide:
Adapting to regional pharmacopoeias requiring harmonized Traditional Chinese Medicine (TCM) dossiers and Halal/Kosher operational integrity:
Harnessing advanced automation, indigenous agricultural sourcing networks, and real-time process monitoring to deliver unmatched cost-to-potency advantages.
Our collaborative industrial manufacturing facilities integrate fully automated multi-stage countercurrent extraction cascades governed by SCADA and PLC control architectures. Unlike manual batch cooking, automated continuous extraction yields superior batch-to-batch homogeneity:
Supply chain security is anchored at the root. Based in Changsha, Hunan—a primary agricultural corridor of China—MedGence commands direct relationships with GAP (Good Agricultural Practices) certified farming cooperatives across varied ecological altitudes:
Over 14+ years of scientific rigor supporting China's foremost pharmaceutical enterprises, academic teaching hospitals, and international supplement innovators.
Engage our laboratories for isolated exploratory assays or complete contract development and commercial manufacturing (CDMO) turnkey pipelines.
Multi-target bioassay-guided fractionation isolating alkaloids, polysaccharides, flavonoids, and terpenoids to discover prime active components with maximum pharmacologic density.
Comparative HPLC analysis benchmarking raw materials collected across differing geographic soil chemistries, seasons, and plant organs (roots, bark, foliage, fruits).
Developing, validating, and transferring HPTLC, HPLC-UV/CAD, GC, and LC-MS assay methods conforming fully to ICH Q2(R1) guidelines for linearity, precision, and robustness.
Engineering pilot-scale extraction, column chromatography resin purification, membrane ultrafiltration, and crystallization to maximize target yield while slashing unit costs.
Eliminating active ingredient degradation, poor flowability, hygroscopicity, and unpleasant organoleptic profiles to formulate high-stability commercial delivery forms.
GLP-compliant preclinical toxicology profiling: Median Lethal Dose (LD50), Acute Oral Toxicity, 28/90-Day Subchronic Repeat-Dose, Ames Bacterial Mutation, and Micronucleus assays.
Rapid mechanistic validation utilizing primary and immortalized cell lines—including antioxidant (ORAC/cellular ROS), anti-inflammatory (TNF-α/IL-6 inhibition), and enzyme inhibition (α-glucosidase).
Validated disease model testing in rodents (metabolic syndromic mice, high-fat diet obesity, cognitive deficit models, arthritis) to confirm in vivo therapeutic bioactivity.
Protocol design, Institutional Review Board (IRB) submission, patient recruiting, and double-blind GCP clinical trial monitoring for functional food claims or formal New Drug Applications (NDA).
Translating historical poly-herbal synergies (Monarch, Minister, Assistant, Envoy philosophy) into modern pharmaceutical formulations showing synergistic pharmacological curves.
Reliable commercial supply of standardized liquid concentrates, paste extracts, spray-dried atomized powders, and volatile essential oils with full analytical batch records.
Complete contract manufacturing packaging finished products in oral liquids, functional shots, two-piece hard capsules, softgels, micro-tablets, sachet powders, and soluble granules.
Clear stage-gate deliverables designed to reduce development risk and provide corporate stakeholders with verifiable regulatory documentation at every step.
Chemical characterization of target active fractions, origin benchmarking, and establishing the raw material baseline.
Establishment of HPLC/HPTLC/GC chromatographic fingerprints, marker identification, and method validation protocol.
DoE multi-parameter optimization across extraction temperatures, solvent ratios, crystallization parameters, and drying times.
In vitro bioassay confirmation, animal pharmacokinetics, acute oral toxicity (LD50), and mutagenicity screening.
Placebo-controlled human clinical trials for supplement claim substantiation or Phase I–IV clinical data sets for drug applications.
Cleanroom pilot batch execution, tech transfer, commercial packaging, and ongoing cGMP stability testing programs.
Formulating custom, proprietary botanical combinations aligned with high-volume global consumer health demand and prescription market expansion.
Rising global metabolic syndrome rates fuel surging commercial demand for clinically validated plant-derived insulin sensitizers and GLP-1 adjuvants:
Modern consumers demand clean, non-stimulant focus, sleep architecture enhancement, and hypothalamic-pituitary-adrenal (HPA) axis balance:
Clean-label beauty brands demand standardized natural actives backed by cellular in vitro assays to replace synthetic topicals:
We power contract formulation, method validation, and clinical dossiers for China’s most prestigious pharmaceutical conglomerates and university hospital research divisions.
Tongrentang Group
CR Sanjiu
Sunflower Pharma
Livzon Pharma Group
Dihon Pharmaceutical
Golden Throat Group
Yangtzi River Pharma
Gofar Biological
Humanwell Healthcare
SCIMYTH Pharma
Hanfang Pharma
Luoxin Pharma
Zhongsheng Pharma
Brilliance & Abundance
Apeloa Pharma
Heng Chang Pharma
Baotou TCM Co.
Kamp Medicine
Santo Pharma
Kangshou Pharma
Juwang Pharma
Tcmages Pharma
Ruihe Pharma
CR Jinchan Pharma
Kangmei Pharma
Tianjicaotang Pharma
Kingstone Unite
Shuguang Hospital
Hunan Direct TCM Hospital
First Hospital of Hunan TCM
Second Xiangya Hospital
Second Hospital of Hunan TCM
Zhuzhou Orthopedics TCM
In-depth answers addressing formulation development parameters, analytical validation, regulatory safety, and international tech transfers.
Traditional contract packaging manufacturers merely blend powders and press tablets using third-party ingredients without scientific substantiation. In contrast, an evidence-based CRO/CDMO like MedGence engineers the formulation at the molecular and pharmacokinetic level. We perform active ingredient screening, potency quantification across harvest seasons, analytical method validation (HPLC/HPTLC/GC), cellular in vitro screening, animal PK/PD testing, and GCP clinical trials. This end-to-end integration guarantees that the commercial finished dosage form delivers reproducible active content, verified stability, and defensible health claims that withstand scrutiny from international regulatory authorities (US FDA, EFSA, NMPA).
We operate strictly on an entrusted contract research and manufacturing model under binding international Non-Disclosure Agreements (NDAs). All proprietary formulation parameters, extraction algorithms, chromatographic profiles, and clinical results generated during client programs remain the exclusive property of the client. Research teams work within compartmentalized data environments, and cleanroom production equipment is monitored under strict batch authorization codes to ensure zero risk of recipe leaks or cross-client IP infringement.
Yes. Our in-house regulatory affairs and toxicology teams author comprehensive technical dossiers conforming to US FDA 21 CFR Part 190.6 (NDIN) and European Regulation (EU) 2015/2283. Our data packages include botanical taxonomic authentication, multi-batch chromatographic fingerprint overlays, ICH stability reports, 90-day repeat-dose subchronic animal toxicology, bacterial reverse mutation assays (Ames test, OECD 471), in vitro mammalian micronucleus tests (OECD 487), and heavy metal/pesticide multiresidue Certificates of Analysis.
Our collaborative and proprietary manufacturing facilities produce both standardized raw active pharmaceutical ingredients (APIs/extracts) and commercial finished dosage units. Active ingredients are supplied as vacuum-concentrated liquids, standardized powders, thick pastes, and supercritical volatile oils. Finished consumer dosage formats include oral liquid vials (10–50 mL shots), two-piece vegetarian HPMC/gelatin capsules, hermetically sealed softgels, film-coated tablets, soluble effervescent powders, and micro-granules packaged in individual barrier-laminate stick packs.
Natural botanicals naturally vary due to rainfall, soil composition, and seasonal temperatures. MedGence resolves this through our proprietary Potency Evaluation & Standardization Protocol. We map chemical variation curves using HPTLC and HPLC across multiple harvest origins and seasons. In production, we utilize computerized multi-origin raw herb blending and standardized resin adsorption chromatography, ensuring the finished extract maintains identical active chemical ratios and bio-equivalence regardless of harvest date.
Timelines depend on client scope. For dietary supplement formulation development involving active screening, analytical method setup, and pilot bench stability, typical timelines range from 8 to 14 weeks. If animal efficacy or preclinical GLP toxicology is required, add 12 to 16 weeks. For clients transferring an existing validated herbal formulation directly into our smart manufacturing facility for OEM pilot batches and commercial cGMP packaging, execution can be completed in as little as 4 to 6 weeks.
Select a specific research capability or request full formulation development quotes directly from our Changsha technical laboratories.
